Skip to content
Screener

Supernus Pharmaceuticals SUPN Financing Cash Flow

Financing Cash Flow at other companies

AbbVie logo
AbbVieABBV
$919M+173%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$1.41M+2,340%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$10.49M-34.2%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$2.99M-89.8%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
-$86.1M+27.0%
XER
Xeris Biopharma Holdings, Inc.XERS
-$8.84M-182%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.72B+14.3%
Enterprise value$2.57B+13.6%
P/S3.5×-0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356576-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from issuance of common stock13,6702,042
Employee taxes paid related to net share settlement of equity awards(4,555)(3,341)
Payment of contingent consideration(20,100)
Net cash provided by (used in) financing activities9,115(21,399)
Net change in cash, cash equivalents, and restricted cash56,42146,517
Cash and cash equivalents at beginning of year129,89869,331
Cash, cash equivalents, and restricted cash at end of year$186,319$115,848
Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Supernus Pharmaceuticals's financing cash flow?
Supernus Pharmaceuticals (SUPN) reported financing cash flow of $9.12M in Q1 2026.
How has Supernus Pharmaceuticals's financing cash flow changed year-over-year?
Supernus Pharmaceuticals's financing cash flow increased by 142.6% year-over-year, from -$21.4M to $9.12M.
What is the long-term trend for Supernus Pharmaceuticals's financing cash flow?
Over 3 years (2021 to 2025), Supernus Pharmaceuticals's financing cash flow has grown at a -58.8% compound annual growth rate (CAGR), from -$130.42M to $9.13M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Supernus Pharmaceuticals's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude